Navigation Links
ASBM Survey Reveals Key Safety Concern Associated with Biosimilar Naming; Urges Distinct Naming Requirement
Date:9/13/2012

WASHINGTON, Sept. 13, 2012 /PRNewswire/ -- The Alliance for Safe Biologic Medicines (ASBM) today announced the results of a new survey on physician opinions relating to biologics and biosimilars. ASBM Chairman, Dr. Richard O. Dolinar, presented key findings during the DIA/FDA Biosimilars Conference: Guidances, Science, and BsUFA in Washington, D.C., where he urged the FDA to make patient-safety the cornerstone of the biosimilars pathway.

The survey examined physician practices and perspectives with regard to biosimilar medicine identification and substitution – policy issues that remain unresolved and will have a fundamental impact on patient safety.  Over 350 endocrinologists, dermatologists, oncologists, rheumatologists, nephrologists and neurologists – all specialties that prescribe biologics – responded to the survey.   Key findings from the physician survey demonstrate that patient safety must be a priority for all biosimilar policies.

  • Inappropriate substitution is a major risk if different biologics have the same scientific name.
    • 64% of surveyed physicians assume if products have the same name a patient can be safely switched from one product to another during treatment. 
    • More than 76% view products with the same scientific name as structurally identical.
  • Names are the primary means of product identification for physicians.
    • The vast majority (99%) of physicians refer to biologic medicines by name for both recording in charts and for reporting adverse events. 
    • Less than 1% of prescribers use national drug code numbers for records or reporting. 
  • Physicians are very concerned about a patient being switched from one biologic to another. 
    • 85% of responding physicians want the authority to designate a biologic medicine as "Dispensed as Written", just as they have it for chemical products.
    • 86% of physicians want to be notified BEFORE a patient is switched to a biologic other than the one prescribed EVEN IF there are no known concerns associated with the product.

Dr. Dolinar, chairman of the Alliance, released the following statement about the conference and the survey results:

"In the past 30 years, biologic medicines have revolutionized the treatment of patients with many diseases – but making copies of these highly complex medicines presents significant challenges for physicians and regulators.  This survey provides important information for effectively addressing these challenges.  Biologics are produced from living cells and copies will be only similar, not identical to the original.  This survey clearly indicates that physicians familiar with biologics know minor changes can make a big difference for sick patients. 

"We have been very supportive of the FDA's efforts to create a pathway that ensures biosimilars are safe and effective for patients.  This survey demonstrates the potential safety consequences of giving different biologic products the same scientific name.  In order to avoid inappropriate substitution, all biologics should be required to have distinct names."

Biologics are used to treat cancer, rheumatoid arthritis and other debilitating diseases. On February 9, 2012, the FDA announced the publication of draft guidance documents relating to the developments of biosimilars, which are similar to, but not exact copies of biologics. The guidance documents were a significant step in establishing a biosimilars pathway and as the FDA moves forward, ASBM will continue to work to ensure patient safety remains the priority.

The survey was conducted by Industry Standard Research. Read the study here.

About the Alliance for Safe Biologic Medicines

The Alliance for Safe Biologic Medicines (ASBM) is an organization composed of diverse healthcare groups and individuals from patients to physicians, innovative medical biotechnology companies, and others who are working together to ensure patient safety is at the forefront of the biosimilars policy discussion. Visit us at www.SafeBiologics.org

CONTACT: (703) 851-9116
media@safebiologics.org


'/>"/>
SOURCE The Alliance for Safe Biologic Medicines
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. According to New Survey, Most Men are Not Proactive about Their Health Despite the Desire to Live Long Lives
2. Fenwick & West Life Science Venture Financing Survey Shows Mild Improvement in Valuations Amid Overall Difficult Financing Environment
3. New Survey Reveals How Patients Choose Their Pharmacy; AccentHealth Garners Consumer Insights from the Waiting Room
4. Survey: Hospital Executives Nationwide Facing Operating Room Case Volume Increases, Seeking Greater Efficiency through Healthcare Information Technology (HIT)
5. Heraeus Survey Invites Customers to Share "What they Really Think"
6. Diplomat Specialty Pharmacys 2012 Physician Satisfaction Survey Results Affirm Success of Companys Education & Training Program
7. U.S. End-User Dental Materials Survey Report 2012
8. U.S. Physician Survey: Stents by Brand, Length, Diameter, Type and Coating 2012
9. Hologic Breast Tomosynthesis (3D Mammography) System Places First in KLAS Annual Survey of Mammography Equipment Users
10. Buyer Spend Activity and Procurement Behaviors and Strategies in the Pharmaceutical Industry - 2012-2013 : Survey Intelligence
11. Supplier Marketing Spend Activity, Marketing and Sales Behaviors and Strategies in the Medical Devices Industry - 2012-2013 : Survey Intelligence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , Germany and ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... a licensing and co-development agreement with Therawis Diagnostics GmbH to ... will be to develop and market PITX2 as a marker ... other high-risk breast cancer patients. "We are pleased ...
(Date:5/25/2016)... 2016 According to market research ... and Demand Forecast to 2022 - Industry Insights by ... published by P&S Market Research, the global insulin delivery ... and it is expected to grow at a CAGR ... pump segment is expected to witness the fastest growth ...
(Date:5/25/2016)... Texas , May 25, 2016 ... the issuance to it by the US Patent ... The company,s technology includes proprietary processes for electronic ... for health and wellness programs, HIPAA compliance and ... "Our technology ...
Breaking Medicine Technology:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... According to ... In an industry filled with chemical-laden beauty products, one company is going against the ... for you: Mad Hippie. The rising star in the green space is proud to ...
(Date:5/26/2016)... Lake MN (PRWEB) , ... May 26, 2016 , ... ... Stance Angle chair , furniture that may support women during pregnancy. Potential benefits ... legs and feet, improved rest and comfort and healthier levels of sitting and standing. ...
(Date:5/25/2016)... (PRWEB) , ... May 26, 2016 , ... The United ... treatment of androgenetic alopecia in both men and women. To date, the company is ... with FDA clearance for any adult who suffers with androgenetic alopecia. , “This ...
(Date:5/25/2016)... ... May 25, 2016 , ... “We ... Managing Partner at HealthScape Advisors. “Brad brings significant experience advising healthcare provider clients ... system accelerates with the implementation of MACRA, we believe that continuing to add ...
(Date:5/25/2016)... Kansas City, MO (PRWEB) , ... May 25, 2016 , ... ... professional, collegiate, and amateur athletics, The National Center for Drug Free Sport (Drug Free ... Drug Free Sport”. This conference, to be held July 12 – 13 in Kansas ...
Breaking Medicine News(10 mins):